MD

Michael J. Donovan

Chief Medical Officer at Renalytix

Michael J. Donovan, Ph.D., M.D. has served as Chief Medical Officer since the company's inception. Since November 2011, Donovan has also served as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mount Sinai. In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc. and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan received a B.S. in Zoology, an M.S. in Endocrinology and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his M.D. from the University of Medicine and Dentistry of New Jersey.


Org chart


Teams


Offices

This person is not in any offices


Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the founder and global leader in the new field of bioprognosis™ for kidney health.


Industries

Employees

51-200

Links